Actuate Therapeutics Inc Financials
Financial Health Signals
Actuate Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Actuate Therapeutics Inc generates $0.80 in operating cash flow (-$21.8M OCF vs -$27.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Actuate Therapeutics Inc earns $-1344.3 in operating income for every $1 of interest expense (-$25.2M vs $19K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Actuate Therapeutics Inc (ACTU) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Actuate Therapeutics Inc reported -$27.3M in net income in fiscal year 2024. This represents a decrease of 10.3% from the prior year.
Actuate Therapeutics Inc earned $-3.26 per diluted share (EPS) in fiscal year 2024. This represents an increase of 81.1% from the prior year.
Actuate Therapeutics Inc held $8.6M in cash against $0 in long-term debt as of fiscal year 2024.
Actuate Therapeutics Inc had 20M shares outstanding in fiscal year 2024. This represents an increase of 1055.2% from the prior year.
Actuate Therapeutics Inc invested $18.7M in research and development in fiscal year 2024. This represents a decrease of 14.0% from the prior year.
ACTU Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.2M-42.0% | $3.8M | N/A | $5.8M |
| SG&A Expenses | $3.3M+101.4% | $1.6M | N/A | $714K |
| Operating Income | -$5.5M-1.5% | -$5.4M | N/A | -$6.5M |
| Interest Expense | $5K+45.1% | $3K | N/A | $5K |
| Income Tax | N/A | N/A | N/A | N/A |
| Net Income | -$5.4M+9.4% | -$6.0M | N/A | -$6.3M |
| EPS (Diluted) | $-0.25+54.5% | $-0.55 | N/A | $-4.31 |
ACTU Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|
| Total Assets | $17.7M+90.1% | $9.3M+211.1% | $3.0M | N/A |
| Current Assets | $17.4M+89.4% | $9.2M+207.4% | $3.0M | N/A |
| Cash & Equivalents | $16.9M+95.9% | $8.6M+192.1% | $3.0M-65.1% | $8.5M |
| Inventory | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.8M-26.4% | $9.2M-91.0% | $102.6M | N/A |
| Current Liabilities | $6.4M-27.6% | $8.8M+27.2% | $6.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Total Equity | $10.9M+10396.9% | $104K+100.1% | -$99.6M-8.1% | -$92.1M |
| Retained Earnings | -$150.1M-13.4% | -$132.4M-26.0% | -$105.1M | N/A |
ACTU Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|
| Operating Cash Flow | -$6.7M-39.9% | -$4.8M+13.4% | -$5.5M+2.2% | -$5.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $17.1M+15738.0% | -$109K | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A |
ACTU Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A |
| Return on Assets | -30.5%+11.3pp | -41.9% | N/A | N/A |
| Current Ratio | 2.74+1.7 | 1.05+0.6 | 0.43 | N/A |
| Debt-to-Equity | 0.62-87.8 | 88.44+89.5 | -1.03 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Actuate Therapeutics Inc profitable?
No, Actuate Therapeutics Inc (ACTU) reported a net income of -$27.3M in fiscal year 2024.
What is Actuate Therapeutics Inc's earnings per share (EPS)?
Actuate Therapeutics Inc (ACTU) reported diluted earnings per share of $-3.26 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Actuate Therapeutics Inc's operating cash flow?
Actuate Therapeutics Inc (ACTU) generated -$21.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Actuate Therapeutics Inc's total assets?
Actuate Therapeutics Inc (ACTU) had $9.3M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Actuate Therapeutics Inc spend on research and development?
Actuate Therapeutics Inc (ACTU) invested $18.7M in research and development during fiscal year 2024.
How many shares does Actuate Therapeutics Inc have outstanding?
Actuate Therapeutics Inc (ACTU) had 20M shares outstanding as of fiscal year 2024.
What is Actuate Therapeutics Inc's current ratio?
Actuate Therapeutics Inc (ACTU) had a current ratio of 1.05 as of fiscal year 2024, which is considered adequate.
What is Actuate Therapeutics Inc's debt-to-equity ratio?
Actuate Therapeutics Inc (ACTU) had a debt-to-equity ratio of 88.44 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Actuate Therapeutics Inc's return on assets (ROA)?
Actuate Therapeutics Inc (ACTU) had a return on assets of -292.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Actuate Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Actuate Therapeutics Inc (ACTU) had $8.6M in cash against an annual operating cash burn of $21.8M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Actuate Therapeutics Inc's Piotroski F-Score?
Actuate Therapeutics Inc (ACTU) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Actuate Therapeutics Inc's earnings high quality?
Actuate Therapeutics Inc (ACTU) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Actuate Therapeutics Inc cover its interest payments?
Actuate Therapeutics Inc (ACTU) has an interest coverage ratio of -1344.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.